Founded in 2024, Analona Therapeutics is a biotech company located in Denmark focused on developing innovative antibody-based therapies for pancreatic cancer.
The company is built on cutting-edge research from the research group of Professor Axel Behrens at the Institute of Cancer Research in the UK, which has identified a range of novel targets and mechanisms of action.
Analona Therapeutics aims to discover and develop antibody based therapeutics against these targets with an initial focus on a key interactor and facilitator of metabolite transporters.
The company was recently accepted into the Venture Lab program of the BioInnovation Institute in Copenhagen.
Subscribe for alerts on new companies featured on Startups.Bio
Roundup of recent venture funding rounds
The biotechnology sector is advancing rapidly, fueled by significant venture capital investments that are enabling companies to achieve major breakthroughs. To stay informed about the latest funding activities and discover …
U-Ploid Biotechnologies
U-Ploid Biotechnologies aims to revolutionize IVF for Age-Related Infertility. Millions of women around the world face the emotional and financial toll of age-related infertility. As more individuals choose to start …
BioTryp Therapeutics
BioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on the development of small molecules to inhibit biofilm formation, which causes 80% of chronic and recurrent infections. BioTryp's …
Bastion Therapeutics
Bastion Therapeutics is a pre-clinical stage biotechnology company focused on developing best-in-class Treg cell therapies, which can target the root causes of inflammatory disorders and autoimmune diseases. Bastion's GRIT™ (Genetically …
View all recently featured startups